摘要
目的经对转移性肾细胞癌患者的治疗,评估治疗前一系列体液和临床参数,以探讨其与临床结果的关系。方法分析86例患者治疗前各相关指标,包括淋巴细胞数、LDH、ESR、白蛋白、C反应蛋白(CRP)和纤维蛋白原,与临床参数中体格状况、肾切除术史、肿瘤位置、数量和无瘤间歇期(DFI)的关系。结果中位生存期12个月。单变量分析表明以下指标和较长的生存有关:良好的体格状况(P=0.022)、肾切除术史(P=0.015)、DFI(P=0.041)、骨转移位置(P=0.027)、少量的转移部位(P=0.045)、白蛋白(P=0.018)、纤维蛋白原(P=0.021)、LDH(P=0.041)和CRP(P=0.001)。多变量分析显示,仅CRP(P=0.003)和DFI(P=0.048)与生存有关。临床和体液参数的相关性分析,结果只有CRP与DFI(P=0.019)和肾切除术史有关(P=0.035)。结论CRP对判断预后的好坏具有一定的价值。
Objective To evaluate a panel of biohumoral and clinical parameters in patients with metastatic renal cell carcinoma before treatment to explore their correlation with clinical outcome. Methods Before 86 patients were treated,lymphocytes,lactate dehydrogenase,the erythrocyte sedimentation rate,albumin,C-reactive protein （CRP） and fibrinogen were analyzed and correlated with clinical parameters, namely performance status, prior nephrectomy, number and site of disease,and disease-free interval（DFI）. Results Median survival were 12 months. On univariate analysis good performance status （P = 0. 022）, prior nephrectomy （P= 0.015）, DFI （P = 0. 041 ）, bone disease sites （P=0. 027） ,a low number of metastatic site （P：0. 045） ,albumin （P=0. 018） ,fibrinogen （P：0. 021）,lactate dehydrogenase （P=0. 041） and CRP （P=0. 001） were related to better survival. On final multivariate analysis only CRP （P=0. 003） and DFI （P=0. 048） were found to have independent role in survival. When we correlated clinical with biohumoral factors, only CRP correlated with DFI （P=0. 019） and prior nephrectomy （P=0. 035）. Conclusions CRP is valuable to discriminate a good or bad state from a poor prognosis.
出处
《现代泌尿生殖肿瘤杂志》
2009年第4期213-215,共3页
Journal of Contemporary Urologic and Reproductive Oncology
关键词
C反应蛋白质
肾肿瘤
预后
C-reactive protein
Kidney neoplasms
Prognosis
